US to buy 10 million courses of Pfizer’s oral Covid-19 drug Paxlovid for $5.3bn
Under the agreement, Pfizer will supply 10 million courses of the investigational Covid-19 drug to the US government,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Nov 21
Under the agreement, Pfizer will supply 10 million courses of the investigational Covid-19 drug to the US government,…
18 Nov 21
The regulatory approval is supported by data from Phase 3 KEEPsAKE-1 and KEEPsAKE-2 studies, evaluating Skyrizi in psoriatic…
18 Nov 21
GSK will supply the doses by 17 December 2021, and the US government holds an option to buy…
17 Nov 21
According to the company, Paxlovid would be the first 3CL protease inhibitor to be used as an oral…
17 Nov 21
The licenses Roche received under the collaboration will be returned to Atea, which will conduct clinical development and…
16 Nov 21
AZD8601 is an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A), jointly developed by AstraZeneca and…
16 Nov 21
Health Canada authorisation was based on scientific evidence shared by Moderna, including data from the Phase 2 clinical…
15 Nov 21
The EC approval follows EMA’s Committee for Medicinal Products for Human Use (CHMP) recommendation to authorise two Covid-19…
12 Nov 21
Ronapreve and Regkirona are the first monoclonal antibody medicines to receive a positive opinion from the CHMP for…
12 Nov 21
The 77.8% vaccine efficacy was based on 130 confirmed cases, where 24 cases were observed in the vaccine…